Enlivex Therapeutics Ltd. (ENLV)
$0.22-12.00%Close
SELLCRISIS · day 90
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $4M
- Beta
- 1.41
- P/E (TTM)
- 0.00
- Short % float
- 0.59%
- Days to cover
- 1.0
- SI change
- +104.5%
- 1W
- -35.29%
- 1M
- -74.42%
- vs SPY 1W
- -35.16%
- vs SPY 1M
- -76.92%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 20
- VALUE
- 29
- GROWTH
- 47
- GARP
- 10
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC126.6%
REV YoY-
ROE211.0%
EPS YoY-
ROA83.8%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM0.00
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.00
P/FCF-
EV/EBITDA-0.78
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E0.44
ALTMAN Z-
CURR RATIO119.39
ND/EBITDA-
BETA1.41
Company news
FAQ
- What is LOPJLB’s current signal on ENLV?
- LOPJLB’s latest quantitative signal on Enlivex Therapeutics Ltd. (ENLV) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ENLV in?
- Enlivex Therapeutics Ltd. (ENLV) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Enlivex Therapeutics Ltd. (ENLV) do?
- Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arise…